Clinical Trials at University of Kansas Cancer Center

As of June 2026, 87 paid clinical trials are recruiting at University of Kansas Cancer Center, located at 3901 RAINBOW BOULEVARD, MAIL STOP 3002, KANSAS CITY, KS 66160-0001, phone (913) 588-6074 in Kansas City, Kansas. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: June 12, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

87 clinical trials at University of Kansas Cancer Center

·Clear filters·↓ Download CSV

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

for Acute Myeloid Leukemia

335 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05564390·Phase 2·Recruiting

Apply to this trial

Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors

for Breast Cancer

673 locations incl. Anchorage

Sponsor: NRG Oncology

Sex: All·Age: 18 - 100

Code: NCT05896189·Recruiting

Apply to this trial

Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)

for Malignant Solid Neoplasm

384 locations incl. Anchorage

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All·Age: All ages·Accepts healthy volunteers

Code: NCT06295367·Recruiting

Apply to this trial

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

for Muscle Invasive Bladder Urothelial Carcinoma

490 locations incl. Phoenix

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05987241·Phase 2, Phase 3·Recruiting

Apply to this trial

Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial

for Nodular Lymphocyte Predominant B-Cell Lymphoma

Drug: Mosunetuzumab

35 locations incl. Duarte

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05886036·Phase 2·Recruiting

Apply to this trial

Obeticholic Acid for Prevention in Barrett's Esophagus

for Barrett Esophagus

8 locations incl. Kansas City

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+·Accepts healthy volunteers

Code: NCT04939051·Phase 2·Recruiting

Apply to this trial

Vitamin D for Prostate Endocrine Therapy

for Stage I Prostate Cancer AJCC v8

51 locations incl. Newark

Sponsor: University of Rochester

Sex: Male·Age: 50+

Code: NCT05838716·Phase 3·Recruiting

Apply to this trial

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

for Prostate Adenocarcinoma

388 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: Male·Age: 18+

Code: NCT05946213·Phase 3·Recruiting

Apply to this trial

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

for Anatomic Stage II Breast Cancer AJCC v8

Drug: Durvalumab

536 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06058377·Phase 3·Recruiting

Apply to this trial

Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer

for Stage IIC Prostate Cancer AJCC v8

Drug: Relugolix

1 location in Kansas City

Sponsor: University of Kansas Medical Center

Sex: Male·Age: 18+

Code: NCT06129851·Phase 2·Not Yet Recruiting

Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers

for Metastatic Colorectal Carcinoma

22 locations incl. Irvine

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05803382·Phase 1·Recruiting

Apply to this trial

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

for Mantle Cell Lymphoma

237 locations incl. Little Rock

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 60+

Code: NCT05976763·Phase 3·Recruiting

Apply to this trial

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

for Breast Cancer

1208 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: Female·Age: 18 - 60

Code: NCT05879926·Phase 3·Recruiting

Apply to this trial

Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors

for Hodgkin Lymphoma

428 locations incl. Anchorage

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All·Age: 18+

Code: NCT06002828·Recruiting

Apply to this trial

Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness

for Advanced Malignant Solid Neoplasm

23 locations incl. Irvine

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05691491·Phase 1, Phase 2·Recruiting

Apply to this trial

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

for Locally Advanced Lung Non-Small Cell Carcinoma

470 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT05624996·Phase 3·Recruiting

Apply to this trial

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

for Anatomic Stage II Breast Cancer AJCC v8

820 locations incl. Birmingham

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT05812807·Phase 3·Recruiting

Apply to this trial

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

for Diffuse Large B-Cell Lymphoma

87 locations incl. Tucson

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT05633615·Phase 2·Recruiting

Apply to this trial

Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy

for Malignant Solid Neoplasm

36 locations incl. Birmingham

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT05642611·Phase 3·Recruiting

Apply to this trial

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

for Recurrent Lung Non-Small Cell Carcinoma

454 locations incl. Daphne

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT05642572·Phase 2·Recruiting

Apply to this trial

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

for Metastatic Salivary Gland Carcinoma

150 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT05408845·Phase 2·Recruiting

Apply to this trial

Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

for Advanced Malignant Solid Neoplasm

36 locations incl. Duarte

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05327010·Phase 2·Recruiting

Apply to this trial

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

for Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

17 locations incl. Tampa

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05172245·Phase 1·Recruiting

Apply to this trial

Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps

for Adenocarcinoma of the Colon

472 locations incl. Fairbanks

Sponsor: NRG Oncology

Sex: All·Age: 45 - 70

Code: NCT05080673·Recruiting

Apply to this trial

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

for Recurrent Ovarian High Grade Serous Adenocarcinoma

27 locations incl. Phoenix

Sponsor: National Cancer Institute (NCI)

Sex: Female·Age: 18+

Code: NCT04633239·Phase 1·Recruiting

Apply to this trial

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

for Stage I Breast Cancer

812 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: All·Age: 50 - 70

Code: NCT04852887·Phase 3·Recruiting

Apply to this trial

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

for Pancreatic Acinar Cell Carcinoma

452 locations incl. Anchorage

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04858334·Phase 2·Recruiting

Apply to this trial

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

for Recurrent Head and Neck Squamous Cell Carcinoma

178 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18 - 79

Code: NCT04671667·Phase 2·Recruiting

Apply to this trial

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

for Chronic Lymphocytic Leukemia

621 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04269902·Phase 3·Recruiting

Apply to this trial

Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma

for Retroperitoneal Sarcoma

109 locations incl. Birmingham

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Sex: All·Age: 18+

Code: NCT04031677·Phase 3·Recruiting

Apply to this trial

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

for Locally Advanced Pancreatic Adenocarcinoma

Drug: Peposertib

44 locations incl. Duarte

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04172532·Phase 1, Phase 2·Recruiting

Apply to this trial

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

for Metastatic Castration-Resistant Prostate Carcinoma

32 locations incl. Duarte

Sponsor: National Cancer Institute (NCI)

Sex: Male·Age: 18+

Code: NCT04071236·Phase 1, Phase 2·Recruiting

Apply to this trial

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

for Buccal Mucosa Squamous Cell Carcinoma

105 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT04333537·Phase 2, Phase 3·Recruiting

Apply to this trial

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

for Ovarian Carcinoma

539 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: Female·Age: 35 - 50

Code: NCT04251052·Recruiting

Apply to this trial

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

for Lung Non-Small Cell Carcinoma

1150 locations incl. Anchorage

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04267848·Phase 3·Recruiting

Apply to this trial

Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial

for Prostate Adenocarcinoma

Drug: Apalutamide

345 locations incl. Phoenix

Sponsor: NRG Oncology

Sex: Male·Age: 18+

Code: NCT04134260·Phase 3·Recruiting

Apply to this trial

A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression

for Treatment Resistant Depression

98 locations incl. Birmingham

Sponsor: LivaNova

Sex: All·Age: 18+

Code: NCT03887715·Recruiting

Apply to this trial

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

for Autoimmune Disease

Drug: Nivolumab

51 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT03816345·Phase 1·Recruiting

Apply to this trial

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

for B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

275 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT03739814·Phase 2·Recruiting

Apply to this trial

Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery

for Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7

140 locations incl. Tucson

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All·Age: 18+

Code: NCT03493425·Phase 2·Recruiting

Apply to this trial